FindTrial
Sign In

PRL3-ZUMAB

BIOLOGICAL6 trials

Sponsors

National University Hospital, Singapore, National Cancer Centre, Singapore, Intra-IMMUSG Pte Ltd

Conditions

Advanced Malignant Solid TumorAdvanced Solid CancersAdvanced Solid TumorAdvanced Solid TumorsGastric CancerHepatocellular CarcinomaNeovascular Age Related Macular DegenerationSolid Tumor

Phase 1

A First-in-Human Study of PRL3-ZUMAB
Active, not recruitingNCT03191682
National University Hospital, SingaporeAdvanced Solid Tumors
Start: 2017-02-20End: 2027-02-20Target: 38Updated: 2025-09-25
A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
RecruitingNCT07547228
Intra-IMMUSG Pte LtdNeovascular Age Related Macular Degeneration
Start: 2025-10-11End: 2027-07-07Target: 15Updated: 2026-04-29

Phase 2

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
CompletedNCT04118114
National Cancer Centre, SingaporeAdvanced Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
Start: 2019-09-03End: 2025-10-17Updated: 2026-05-01
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Active, not recruitingNCT04452955
Intra-IMMUSG Pte LtdSolid Tumor
Start: 2020-12-12End: 2026-12-01Updated: 2026-04-22
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
RecruitingNCT07290088
Intra-IMMUSG Pte LtdAdvanced Solid Cancers
Start: 2023-01-09End: 2026-12-01Target: 52Updated: 2026-04-16
PRL3-Zumab in Patients With Advanced Solid Tumors
Active, not recruitingNCT07541001
Intra-IMMUSG Pte LtdAdvanced Malignant Solid Tumor
Start: 2021-08-30End: 2026-12-01Target: 60Updated: 2026-04-23

Related Papers

The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.
2025-05-08
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
2023-04-1512 citations